The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.
|Articles|October 27, 2011
Cost Control Incentives for Doctors, Hospitals Don't Affect Patient Outcomes when Quality Variables Are Implemented
Advertisement
Findings from a 4-year study suggest that pay for performance (P4P) incentive programs help reduce costs without impacting complications and death rates from major surgeries when quality care variables are implemented.
The researchers, formed from a group of hospitals in New York City, presented their findings at the 2011 Annual Clinical Congress of the American College of Surgeons.
Read the full story at:
Sources: American College of Surgeons; Newswise
Advertisement
Related to this article
Incidence of diabetic macular edema and the need for glaucoma surgery were reduced after treatment with glucagon-like peptide-1 receptor agonists.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
Patients with Sjögren disease diagnosed over a year after symptom onset had 2.3 times the odds of moderate or greater disease activity, a US survey found.
An estimated 44,052 sports eye injuries were treated in 2025 and 1262 pickleball eye injuries in 2024; 99% of lawnmower eye injuries were at home.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
3
Multi-Hit TP53 Linked to Shorter Survival in Chronic-Phase MPN Cohorts
4
Full POLARGO Data Reveal OS, Safety for Pola-R-GemOx in DLBCL
5